CONSIDERATIONS TO KNOW ABOUT ABBV-744 BRD4 INHIBITOR CANCER THERAPY EFFICACY

In Phase A, participants will receive distinctive doses and schedules of oral ABBV-744 pill to discover Protected dosing regimen. Added contributors will likely be enrolled on the identified monotherapy dosign routine. In Phase B, individuals will receive oral ruxolitinib and ABBV-744 will be given as "insert-on" therapy. In Segment C, contributors